Bart Barlogie Selected Research

Venous Thromboembolism

1/2012	Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.
8/2006	Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bart Barlogie Research Topics

Disease

145	Multiple Myeloma 12/2023 - 02/2002
55	Neoplasms (Cancer) 01/2023 - 01/2002
20	Chromosome Aberrations (Chromosome Abnormalities) 01/2024 - 08/2002
10	Bone Diseases (Bone Disease) 09/2014 - 01/2002
8	Paraproteinemias (Monoclonal Gammopathy) 11/2020 - 02/2006
7	Disease Progression 01/2015 - 01/2002
6	Amyloidosis 06/2014 - 03/2002
5	Thrombocytopenia (Thrombopenia) 01/2024 - 12/2005
5	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2018 - 04/2003
5	Anemia 01/2018 - 04/2003
5	Monoclonal Gammopathy of Undetermined Significance 01/2018 - 01/2002
5	Aspergillosis 10/2011 - 07/2007
4	Hematologic Neoplasms (Hematological Malignancy) 12/2019 - 07/2007
4	Smoldering Multiple Myeloma 01/2018 - 10/2008
4	Renal Insufficiency (Renal Failure) 11/2010 - 01/2003
4	Venous Thrombosis (Deep-Vein Thrombosis) 03/2006 - 08/2002
3	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2019 - 01/2008
3	Leukemia 03/2015 - 08/2012
3	Bone Resorption 06/2013 - 02/2002
3	Testicular Neoplasms (Testicular Cancer) 05/2011 - 08/2002
3	Fatigue 05/2011 - 04/2003
3	Mucositis 02/2011 - 01/2003
3	Neoplasm Metastasis (Metastasis) 01/2008 - 12/2003
3	Thrombosis (Thrombus) 10/2007 - 06/2003
3	Peripheral Nervous System Diseases (PNS Diseases) 07/2006 - 04/2003
3	Infections 08/2004 - 03/2003
2	Carcinogenesis 01/2020 - 04/2006
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2019 - 06/2002
2	Plasmacytoma 01/2017 - 02/2007
2	Plasma Cell Leukemia 12/2015 - 06/2014
2	Castleman Disease (Castleman's Disease) 01/2013 - 07/2010
2	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 09/2012 - 12/2002
2	Venous Thromboembolism 01/2012 - 08/2006
2	Neutropenia 12/2010 - 08/2004
2	Activated Protein C Resistance (APC Resistance) 08/2006 - 06/2003

Drug/Important Bio-Agent (IBA)

27	Thalidomide (Thalomid)FDA Link 12/2023 - 04/2002
23	Bortezomib (Velcade)FDA Link 12/2023 - 06/2003
16	Dexamethasone (Maxidex)FDA LinkGeneric 12/2023 - 03/2003
14	Melphalan (Alkeran)FDA LinkGeneric 12/2023 - 03/2002
12	Lenalidomide (CC 5013)FDA Link 12/2023 - 10/2003
11	Proteins (Proteins, Gene)FDA Link 12/2016 - 05/2002
9	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2024 - 03/2004
9	Proteasome InhibitorsIBA 09/2017 - 03/2005
8	AntigensIBA 01/2018 - 05/2002
5	Messenger RNA (mRNA)IBA 04/2010 - 02/2003
4	CytokinesIBA 01/2019 - 06/2003
4	Proteasome Endopeptidase Complex (Proteasome)IBA 12/2016 - 04/2009
4	galactomannanIBA 10/2011 - 07/2007
4	Immunoglobulins (Immunoglobulin)IBA 07/2008 - 06/2003
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2023 - 06/2003
3	AlbuminsIBA 01/2018 - 02/2011
3	CreatinineIBA 01/2018 - 03/2002
3	Immunomodulating AgentsIBA 09/2017 - 12/2002
3	DNA (Deoxyribonucleic Acid)IBA 04/2017 - 01/2004
3	Monoclonal AntibodiesIBA 01/2016 - 10/2006
3	Antineoplastic Agents (Antineoplastics)IBA 02/2011 - 08/2005
3	Cyclin D1IBA 02/2010 - 01/2003
3	Prednisone (Sone)FDA LinkGeneric 07/2009 - 05/2002
2	Etoposide (VP 16)FDA LinkGeneric 12/2023 - 06/2003
2	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2023 - 06/2003
2	Cisplatin (Platino)FDA LinkGeneric 12/2023 - 06/2003
2	RNA (Ribonucleic Acid)IBA 01/2023 - 10/2006
2	Immunoglobulin G (IgG)IBA 11/2020 - 10/2016
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 02/2007
2	Immunoglobulin M (IgM)IBA 01/2018 - 08/2014
2	Cyclin DIBA 04/2017 - 07/2005
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2017 - 08/2004
2	Histones (Histone)IBA 12/2016 - 05/2011
2	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 07/2014 - 07/2008
2	NF-kappa B (NF-kB)IBA 07/2013 - 08/2007
2	Indicators and Reagents (Reagents)IBA 01/2012 - 04/2004
2	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2012 - 05/2008
2	Sodium Glutamate (Accent)IBA 10/2011 - 12/2010
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2010 - 07/2006
2	VaccinesIBA 09/2010 - 11/2005
2	beta CateninIBA 03/2010 - 04/2009
2	Cyclin D3IBA 02/2010 - 01/2003
2	C-Reactive ProteinIBA 09/2009 - 10/2006
2	elotuzumabIBA 09/2009 - 05/2008
2	fludarabineIBA 12/2008 - 04/2003
2	LigandsIBA 12/2008 - 02/2002
2	Polysaccharides (Glycans)IBA 05/2008 - 07/2007
2	Heparitin Sulfate (Heparan Sulfate)IBA 09/2007 - 12/2003
2	heparanaseIBA 09/2007 - 12/2003
2	EnzymesIBA 09/2007 - 12/2003
2	Syndecan-1 (Syndecan 1)IBA 09/2007 - 12/2003
2	OligonucleotidesIBA 04/2007 - 12/2003
2	factor V LeidenIBA 08/2006 - 06/2003
2	Protein CIBA 08/2006 - 06/2003

Therapy/Procedure

95	Therapeutics 12/2023 - 01/2002
23	Drug Therapy (Chemotherapy) 03/2022 - 08/2002
10	Stem Cell Transplantation 03/2022 - 01/2002
7	Transplantation 12/2015 - 01/2002
7	Autologous Transplantation 08/2014 - 05/2003
6	Immunotherapy 09/2012 - 05/2002
3	Hematopoietic Stem Cell Transplantation 12/2023 - 03/2006
3	Cell Transplantation 12/2015 - 03/2006
2	Salvage Therapy 07/2013 - 10/2008
2	Induction Chemotherapy 02/2011 - 05/2002
2	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 05/2008 - 03/2004